Advanced Prostate Cancer Treatment: Options When Cancer Is High Risk or Has Spread

Advanced prostate cancer is not one situation but three: cancer that is high risk or locally advanced, cancer that has spread but still responds to hormone therapy, and cancer that keeps growing despite hormone therapy. Each has its own treatment playbook.

Today that playbook includes androgen deprivation therapy (ADT) paired with newer pills such as abiraterone (Zytiga), enzalutamide (Xtandi), apalutamide (Erleada) and darolutamide (Nubeqa), along with chemotherapy, PSMA-targeted radioligand therapy and genetically targeted drugs. The best treatment for stage 4 prostate cancer depends on which of these situations applies, how far the cancer has spread, and what has already been tried.

This guide walks through each stage in plain language, so the options an oncologist raises make sense and the next conversation is easier to have.

Which kind of advanced prostate cancer is it?

Doctors usually sort advanced disease into three groups, because the treatment logic changes at each step:

High-risk or locally advanced: the cancer has grown through the edge of the prostate or into nearby lymph nodes, but scans show no spread to distant organs or bones. The goal is still long-term control and, for many men, cure.
Metastatic hormone-sensitive (also called castration-sensitive): the cancer has spread, often to bones or distant lymph nodes, but still shrinks or slows when testosterone is lowered.
Castration-resistant: the cancer keeps growing even though testosterone is at very low levels. This is where many of the newest treatments are used.

Knowing which group applies is the single most useful fact to bring to any discussion of treatment, because the same drug can be first-line in one group and a later option in another.

Treating locally advanced and high-risk prostate cancer

For cancer that has not spread to distant sites, treatment usually combines a local therapy with hormone therapy. The two most common paths are:

Radiation plus long-term hormone therapy. External beam radiation to the prostate (and sometimes the pelvic lymph nodes) is paired with ADT, often for 18 months to three years. For some very high-risk cases, doctors may add abiraterone for a period of time.
Surgery with lymph node removal. A radical prostatectomy removes the prostate and nearby lymph nodes. If the PSA does not fall to very low levels afterward, or the pathology shows higher risk, radiation and hormone therapy may follow.

Which path fits depends on age, overall health, how far the cancer extends, and personal priorities around side effects. Many treatment centers have a urologist and a radiation oncologist review the case together before a decision is made.

Treatment for prostate cancer that has spread

When prostate cancer has spread but still responds to hormone therapy, ADT is the foundation. Lowering testosterone, with injections or with surgery to remove the testicles, slows the cancer for a time but does not cure it on its own.

The biggest change of the last decade is that ADT is now usually combined with another treatment from the start, rather than holding other options in reserve. Common combinations include:

ADT plus an androgen receptor pathway inhibitor: abiraterone with prednisone, enzalutamide, apalutamide, or darolutamide. These are daily pills that block the cancer's ability to use the small amounts of androgen that remain.
ADT plus chemotherapy: docetaxel, typically given for six cycles, sometimes together with darolutamide or abiraterone for men with a larger amount of cancer.
Radiation to the prostate itself: for men whose cancer has spread to only a few sites, treating the prostate with radiation alongside systemic therapy may help.

The choice between these depends on how much cancer there is, where it has spread, heart and liver health, other medications, and how a man feels about side effects such as fatigue, hot flashes and changes in blood pressure or blood sugar.

When hormone therapy stops working

Over time, most metastatic prostate cancers find ways to grow despite low testosterone. At that point, treatment usually continues ADT and adds or switches to other therapies.

A different hormone-pathway drug, if one has not already been used.
Chemotherapy with docetaxel or, later, cabazitaxel (Jevtana).
PSMA-targeted radioligand therapy. Lutetium Lu 177 vipivotide tetraxetan (Pluvicto) attaches to a protein called PSMA on prostate cancer cells and delivers radiation directly to them. It is used for PSMA-positive cancer after a hormone-pathway drug, and a PSMA PET scan is used to check eligibility.
PARP inhibitors such as olaparib (Lynparza), rucaparib (Rubraca), talazoparib (Talzenna, given with enzalutamide) and niraparib with abiraterone (Akeega). These are used when the cancer carries certain DNA-repair gene changes, such as BRCA2.
Radium-223 (Xofigo) for cancer that has spread mainly to bone and is causing symptoms.
Immunotherapy, including sipuleucel-T (Provenge) for some men with few symptoms, and pembrolizumab (Keytruda) for the small number of cancers with specific genetic features.

The order in which these are used is highly individual. A drug that was right as a second treatment for one man may be a fourth option for another, depending on what came before and how the cancer responded.

Tests that shape the treatment choice

Three kinds of results now steer treatment for advanced disease more than ever:

PSA trends. How quickly PSA rises, and how far it falls on treatment, help show whether a therapy is working. A single number matters less than the pattern over time; this guide explains what PSA numbers mean once cancer is advanced.
PSMA PET imaging. This newer scan finds small areas of cancer that standard CT and bone scans can miss, and it determines eligibility for PSMA-targeted therapy.
Genetic testing. Testing of the tumor and of inherited genes is recommended for men with metastatic prostate cancer. A positive result can open the door to PARP inhibitors or immunotherapy, and may matter for family members as well.

Protecting bones and managing side effects

Long-term hormone therapy weakens bones, and prostate cancer often spreads to bone. Many men are offered calcium, vitamin D, weight-bearing exercise, and bone-strengthening medicines such as denosumab or zoledronic acid. Fatigue, hot flashes, weight gain and mood changes are common with hormone therapy, and most can be eased once they are raised with the care team.

Questions to ask the oncology team

Advanced prostate cancer involves a sequence of decisions rather than one. These questions help keep each one clear:

Is the cancer hormone-sensitive or castration-resistant right now?
Where exactly has it spread, and would a PSMA PET scan change the plan?
Has genetic testing been done on the tumor and on inherited genes?
Why this combination first, and what would come next if it stops working?
What side effects are most likely, and how will bone health be protected?
Are there clinical trials that would be a good fit at this stage?

Many men with advanced disease are cared for by a medical oncologist and a urologist together. For anyone still arranging specialist care, here is how to find an experienced urologist.

Clinical trials and second opinions

Treatment for advanced prostate cancer is changing quickly, and clinical trials are often how the newest options become available. Major cancer centers run trials at every stage of advanced disease, including for men whose cancer has already been through several treatments. A second opinion at a center that treats many men with advanced prostate cancer is common and rarely delays care.

The bottom line

There is no single best treatment for advanced prostate cancer. There is a best next step, and it depends on the stage, the test results, and what has already been tried. Knowing which of the three situations applies, asking about PSMA imaging and genetic testing, and understanding how today's combinations work make it far easier to weigh the options with the care team.

Sources

This article is for general information and is not medical advice. Treatment decisions should be made with a qualified oncology team.